Karachi: GlaxoSmithKline Pakistan Limited (GLAXO) showcased a significant financial upturn during its corporate briefing, revealing a 52% year-on-year increase in net earnings for the calendar year 2025. This was attributed to strategic price adjustments, robust tender sales in the fourth quarter, and effective cost-efficiency measures.

According to JS Global, GLAXO's earnings per share rose to Rs31.48, with the company solidifying its market leadership with a 9% market share by volume and a 6% share in sector revenue. Key brands such as Augmentin and Velosef accounted for 46% and 68% of their respective categories. However, the company faced a 10-15% decline in overall volumes due to slowed sales in certain regions and competition from cheaper local brands.

Despite a decline in antibiotic sales, this segment remains a major revenue contributor, comprising 48% of the total revenue mix. The successful launch of Shingrix, a vaccine for shingles, was noted, though its financial impact is expected to take time to materialize. A significant increase in fourth-quarter revenues was driven by strong tender sales and seasonal factors.

Management highlighted a reduction in promotional allowances from the parent company, indicating improved profitability. However, potential risks from rising energy prices and geopolitical tensions could impact API supply chains and pricing, although current margins remain stable.